Case Report: RAS-associated autoimmune leukoproliferative disorder presenting with early-onset liver failure in a 9-month-old Chinese girl
Authors:
Open Access
- 22 September 2026
- journal article
- case report
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1943641
Abstract
Background: RAS-associated autoimmune leukoproliferative disorder (RALD) is a rare, nonmalignant lymphoproliferative disorder characterized by splenomegaly, autoimmune cytopenia, monocytosis, and somatic RAS pathway mutations. Severe hepatic failure is an uncommon manifestation. Here, we report a critically ill infant with a diagnosis of RALD who presented with fulminant liver failure. Case report: A 9-month-old girl presented with recurrent infections, lymphadenopathy, massive hepatosplenomegaly, cytopenia, coagulopathy, and early-onset liver failure. Disseminated Talaromyces marneffei infection was confirmed by two sets of peripheral blood cultures. Whole-exome sequencing (WES) identified a heterozygous KRAS c.351A>C (p.Lys117Asn, K117N) variant located in the GTP-binding domain. The heterozygous state and clinical context are consistent with a somatic mutation in a subset of hematopoietic cells, rather than a germline variant. The patient died two days after admission despite antibiotics and maximal supportive care, including plasma exchange and intravenous immunoglobulin. Conclusion: This case illustrates that RALD-associated immune dysregulation served as the underlying root cause, on the basis of which a disseminated opportunistic infection developed as the direct cause of the fatal deterioration, revealing a potential link between oncogenic RAS signaling and innate immune dysregulation. It underscores the urgency of early genetic screening in infants with unexplained hepatitis and systemic inflammation, while advocating for novel therapeutic strategies targeting RAS/MAPK pathways.Keywords
This publication has 21 references indexed in Scilit:
- Ras‐associated autoimmune lymphoproliferative disorderBritish Journal of Haematology, 2024
- Histopathological and molecular findings in a patient with Ras-associated autoimmune leukoproliferative disorderHuman Pathology Reports, 2022
- Talaromyces marneffei infection in non–HIV‐infected patients in mainland ChinaMycoses, 2021
- Clinical Spectrum of Ras-Associated Autoimmune Leukoproliferative Disorder (RALD)Journal of Clinical Immunology, 2020
- Non-HIV talaromycosisMedicine, 2020
- Superficial and Deep Cutaneous Involvement by RAS-Associated Autoimmunne Leukoproliferative Disease (RALD Cutis): A Histologic Mimicker of Histiocytoid Sweet SyndromeThe American Journal of Dermatopathology, 2019
- Weekly Rituximab Followed by Monthly Rituximab Treatment for Autoimmune Disease Associated With RAS-associated Autoimmune Leukoproliferative DiseaseJournal of Pediatric Hematology/Oncology, 2018
- Cutaneous involvement in an 8-year-old boy with Ras-associated autoimmune leucoproliferative disorder (RALD)Clinical and Experimental Dermatology, 2018
- NRAS mutation causes a human autoimmune lymphoproliferative syndromeProceedings of the National Academy of Sciences, 2007
- Penicillium marneffeiInfection and Recent Advances in the Epidemiology and Molecular Biology AspectsClinical Microbiology Reviews, 2006